BMS bids $4.5B for ImClone

They're partners on the cancer med Erbitux, so why not join forces completely? Bristol-Myers Squibb has offered $4.5 billion for ImClone Systems, a $60-per-share price that represents about a 40 percent premium over the past month's closing prices. Release | Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.